Related Experiment Video
Updated: Jan 29, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
Published on: September 27, 2017
Dupilumab in Elderly Patients with Atopic Dermatitis-A Systematic Review and Meta-Analysis
Przemysław Hałubiec1,2,3, Natalia Gołąbek4, Anna Wojas-Pelc1,2
1Department of Dermatology, Jagiellonian University Medical College, Botaniczna 3, 31-503 Cracow, Poland.
Dupilumab effectively treats atopic dermatitis (AD) in older adults, significantly improving skin severity and itch. This biologic agent is well-tolerated in patients aged 60 and over, offering a promising therapeutic option.
Area of Science:
- Dermatology
- Clinical Pharmacology
- Geriatrics
Background:
- Atopic dermatitis (AD) is a chronic skin condition impacting patient quality of life.
- Dupilumab is an effective biologic for AD in adults, but data for elderly patients is scarce.
- Elderly individuals with AD represent an understudied population regarding advanced therapies.
Purpose of the Study:
- To systematically evaluate the efficacy and safety of dupilumab in patients aged 60 years and older with AD.
- To synthesize existing published data on dupilumab's use in the elderly AD population.
- To provide evidence-based insights into dupilumab's therapeutic potential for geriatric AD patients.
Main Methods:
- A systematic review and meta-analysis adhering to the PICO(S) framework.
- Inclusion of English-language articles published up to December 31, 2024, focusing on patients ≥60 years with AD treated with dupilumab.
- Random-effects meta-analysis of observational studies, incorporating subgroup and meta-regression analyses.
Main Results:
- Twenty-one articles met the inclusion criteria for the review.
- Dupilumab significantly reduced AD severity (EASI), pruritus (P-NRS), and quality of life impairment (DLQI) after 16 weeks (p < 0.001).
- Common adverse events included conjunctivitis, injection site reactions, and facial flushing; prior cyclosporin A use and generalized-prurigo phenotype predicted poorer outcomes.
Conclusions:
- Dupilumab demonstrates significant effectiveness and good tolerability in elderly patients with atopic dermatitis.
- The findings support dupilumab as a viable treatment option for AD in the geriatric population.
- Further research is recommended to ascertain the long-term efficacy and safety profile of dupilumab in this demographic.
More Related Videos
Related Concept Videos
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Random and Systematic Errors
Directing Effect of Substituents: meta-Directing Groups
Systematic Sampling Method
Systematic sampling is one of the simplest methods...
Propagation of Uncertainty from Systematic Error

